

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Medical technologies evaluation programme

Equality impact assessment: Guidance development

GID-MT561 ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections

The impact on equality has been assessed during this evaluation according to the principles of the [NICE Equality scheme](#).

Medical technology consultation document

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

No equality issues were identified; however, equality considerations were highlighted for the committee.

This device is indicated for use for haemodialysis. Some people with chronic kidney disease have haemodialysis. Kidney disease occurs more frequently in males, people over the age of 60 and those of South-Asian, African or African-Caribbean family origin. People with chronic kidney disease are covered by the Equality Act 2010. The committee was satisfied that the device does not pose an equality issue as access to the device is not restricted

2. Have any other potential equality issues been highlighted in the sponsor's submission, or patient organisation questionnaires, and, if so, how has the committee addressed these?

No other potential equality issues have been identified in the sponsors submission

3. Have any other potential equality issues been identified by the committee and, if so, how has the committee addressed these?

No other equality issues were identified by the committee. One equality consideration was addressed:

ClearGuard HD caps should not be used in people allergic to chlorhexidine. The committee discussed the prevalence of this allergy and considerations around sensitisation to chlorhexidine. This discussion was reflected in the draft guidance, section 4.5.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to or difficulties with access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the medical technology consultation document, and, if so, where?

No

Approved by Associate Director: Anastasia Chalkidou

Date: 8/9/2021